Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.
3 reports, 3 independent
Updated Sep 2
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 4
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sub-event
- NeoGenomics wins a patent lawsuit and submits a product for clinical reimbursement coverage.Sub-event
Natera utilizes Panorama for prenatal testing while facing IP disputes.1 source
Natera confirmed certified lab operations in Austin and San Carlos.1 source
Keep exploring
The entities involved
-
Natera
company in San Carlos, United States
-
NeoGenomics
cancer genetics diagnostic testing company based in Fort Myers, Florida, USA
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyNatera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics Natera, Inc. (NASDAQ:NTRA) is one of the best hot large cap stocks to buy according to hedge funds. On August
- BenzingaNeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents t
- Business WireNatera Provides Update on Patent Litigation with NeoGenomics AUSTIN, Texas, August 29, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, tod